Tags

Type your tag names separated by a space and hit enter

COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses.
Nature. 2020 10; 586(7830):594-599.Nat

Abstract

An effective vaccine is needed to halt the spread of the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) pandemic. Recently, we reported safety, tolerability and antibody response data from an ongoing placebo-controlled, observer-blinded phase I/II coronavirus disease 2019 (COVID-19) vaccine trial with BNT162b1, a lipid nanoparticle-formulated nucleoside-modified mRNA that encodes the receptor binding domain (RBD) of the SARS-CoV-2 spike protein1. Here we present antibody and T cell responses after vaccination with BNT162b1 from a second, non-randomized open-label phase I/II trial in healthy adults, 18-55 years of age. Two doses of 1-50 μg of BNT162b1 elicited robust CD4+ and CD8+ T cell responses and strong antibody responses, with RBD-binding IgG concentrations clearly above those seen in serum from a cohort of individuals who had recovered from COVID-19. Geometric mean titres of SARS-CoV-2 serum-neutralizing antibodies on day 43 were 0.7-fold (1-μg dose) to 3.5-fold (50-μg dose) those of the recovered individuals. Immune sera broadly neutralized pseudoviruses with diverse SARS-CoV-2 spike variants. Most participants had T helper type 1 (TH1)-skewed T cell immune responses with RBD-specific CD8+ and CD4+ T cell expansion. Interferon-γ was produced by a large fraction of RBD-specific CD8+ and CD4+ T cells. The robust RBD-specific antibody, T cell and favourable cytokine responses induced by the BNT162b1 mRNA vaccine suggest that it has the potential to protect against COVID-19 through multiple beneficial mechanisms.

Authors+Show Affiliations

BioNTech, Mainz, Germany. ugur.sahin@biontech.de. TRON gGmbH-Translational Oncology at the University Medical Center of the Johannes Gutenberg, Mainz, Germany. ugur.sahin@biontech.de.BioNTech, Mainz, Germany.BioNTech, Mainz, Germany.BioNTech, Mainz, Germany.BioNTech, Mainz, Germany.BioNTech, Mainz, Germany.Regeneron Pharmaceuticals, Tarrytown, NY, USA.Regeneron Pharmaceuticals, Tarrytown, NY, USA.BioNTech, Mainz, Germany.BioNTech, Mainz, Germany.BioNTech, Mainz, Germany.BioNTech, Mainz, Germany.BioNTech, Mainz, Germany.BioNTech, Mainz, Germany.BioNTech, Mainz, Germany.BioNTech, Mainz, Germany.BioNTech, Mainz, Germany.BioNTech, Mainz, Germany.BioNTech, Mainz, Germany.BioNTech, Mainz, Germany.BioNTech, Mainz, Germany.BioNTech, Mainz, Germany.BioNTech, Mainz, Germany.Bexon Clinical Consulting, Upper Montclair, NJ, USA.BioNTech, Mainz, Germany.BioNTech, Mainz, Germany.BioNTech, Mainz, Germany.BioNTech, Mainz, Germany.CRS Clinical Research Services Mannheim GmbH, Mannheim, Germany.University of Texas Medical Branch, Galveston, TX, USA.University of Texas Medical Branch, Galveston, TX, USA.Pfizer, Pearl River, NY, USA.Pfizer, Pearl River, NY, USA.Pfizer, Pearl River, NY, USA.Pfizer, Pearl River, NY, USA.Pfizer, Pearl River, NY, USA.Pfizer, Pearl River, NY, USA.Regeneron Pharmaceuticals, Tarrytown, NY, USA.Pfizer, Pearl River, NY, USA.Pfizer, Pearl River, NY, USA.Pfizer, Pearl River, NY, USA.BioNTech, Mainz, Germany.

Pub Type(s)

Journal Article

Language

eng

PubMed ID

32998157

Citation

Sahin, Ugur, et al. "COVID-19 Vaccine BNT162b1 Elicits Human Antibody and TH1 T Cell Responses." Nature, vol. 586, no. 7830, 2020, pp. 594-599.
Sahin U, Muik A, Derhovanessian E, et al. COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses. Nature. 2020;586(7830):594-599.
Sahin, U., Muik, A., Derhovanessian, E., Vogler, I., Kranz, L. M., Vormehr, M., Baum, A., Pascal, K., Quandt, J., Maurus, D., Brachtendorf, S., Lörks, V., Sikorski, J., Hilker, R., Becker, D., Eller, A. K., Grützner, J., Boesler, C., Rosenbaum, C., ... Türeci, Ö. (2020). COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses. Nature, 586(7830), 594-599. https://doi.org/10.1038/s41586-020-2814-7
Sahin U, et al. COVID-19 Vaccine BNT162b1 Elicits Human Antibody and TH1 T Cell Responses. Nature. 2020;586(7830):594-599. PubMed PMID: 32998157.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses. AU - Sahin,Ugur, AU - Muik,Alexander, AU - Derhovanessian,Evelyna, AU - Vogler,Isabel, AU - Kranz,Lena M, AU - Vormehr,Mathias, AU - Baum,Alina, AU - Pascal,Kristen, AU - Quandt,Jasmin, AU - Maurus,Daniel, AU - Brachtendorf,Sebastian, AU - Lörks,Verena, AU - Sikorski,Julian, AU - Hilker,Rolf, AU - Becker,Dirk, AU - Eller,Ann-Kathrin, AU - Grützner,Jan, AU - Boesler,Carsten, AU - Rosenbaum,Corinna, AU - Kühnle,Marie-Cristine, AU - Luxemburger,Ulrich, AU - Kemmer-Brück,Alexandra, AU - Langer,David, AU - Bexon,Martin, AU - Bolte,Stefanie, AU - Karikó,Katalin, AU - Palanche,Tania, AU - Fischer,Boris, AU - Schultz,Armin, AU - Shi,Pei-Yong, AU - Fontes-Garfias,Camila, AU - Perez,John L, AU - Swanson,Kena A, AU - Loschko,Jakob, AU - Scully,Ingrid L, AU - Cutler,Mark, AU - Kalina,Warren, AU - Kyratsous,Christos A, AU - Cooper,David, AU - Dormitzer,Philip R, AU - Jansen,Kathrin U, AU - Türeci,Özlem, Y1 - 2020/09/30/ PY - 2020/07/16/received PY - 2020/09/22/accepted PY - 2020/10/1/pubmed PY - 2020/10/1/medline PY - 2020/9/30/entrez SP - 594 EP - 599 JF - Nature JO - Nature VL - 586 IS - 7830 N2 - An effective vaccine is needed to halt the spread of the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) pandemic. Recently, we reported safety, tolerability and antibody response data from an ongoing placebo-controlled, observer-blinded phase I/II coronavirus disease 2019 (COVID-19) vaccine trial with BNT162b1, a lipid nanoparticle-formulated nucleoside-modified mRNA that encodes the receptor binding domain (RBD) of the SARS-CoV-2 spike protein1. Here we present antibody and T cell responses after vaccination with BNT162b1 from a second, non-randomized open-label phase I/II trial in healthy adults, 18-55 years of age. Two doses of 1-50 μg of BNT162b1 elicited robust CD4+ and CD8+ T cell responses and strong antibody responses, with RBD-binding IgG concentrations clearly above those seen in serum from a cohort of individuals who had recovered from COVID-19. Geometric mean titres of SARS-CoV-2 serum-neutralizing antibodies on day 43 were 0.7-fold (1-μg dose) to 3.5-fold (50-μg dose) those of the recovered individuals. Immune sera broadly neutralized pseudoviruses with diverse SARS-CoV-2 spike variants. Most participants had T helper type 1 (TH1)-skewed T cell immune responses with RBD-specific CD8+ and CD4+ T cell expansion. Interferon-γ was produced by a large fraction of RBD-specific CD8+ and CD4+ T cells. The robust RBD-specific antibody, T cell and favourable cytokine responses induced by the BNT162b1 mRNA vaccine suggest that it has the potential to protect against COVID-19 through multiple beneficial mechanisms. SN - 1476-4687 UR - https://www.unboundmedicine.com/medline/citation/32998157/full_citation L2 - https://doi.org/10.1038/s41586-020-2814-7 DB - PRIME DP - Unbound Medicine ER -
Try the Free App:
Prime PubMed app for iOS iPhone iPad
Prime PubMed app for Android
Prime PubMed is provided
free to individuals by:
Unbound Medicine.